Literature DB >> 32513446

A knowledge-based organ dose prediction tool for brachytherapy treatment planning of patients with cervical cancer.

Tahir I Yusufaly1, Karoline Kallis1, Aaron Simon1, Jyoti Mayadev1, Catheryn M Yashar1, John P Einck1, Loren K Mell1, Derek Brown1, Daniel Scanderbeg1, Sebastian J Hild1, Brent Covele1, Kevin L Moore1, Sandra M Meyers2.   

Abstract

PURPOSE: The purpose of this study is to explore knowledge-based organ-at-risk dose estimation for intracavitary brachytherapy planning for cervical cancer. Using established external-beam knowledge-based dose-volume histogram (DVH) estimation methods, we sought to predict bladder, rectum, and sigmoid D2cc for tandem and ovoid treatments. METHODS AND MATERIALS: A total of 136 patients with loco-regionally advanced cervical cancer treated with 456 (356:100 training:validation ratio) CT-based tandem and ovoid brachytherapy fractions were analyzed. Single fraction prescription doses were 5.5-8 Gy with dose criteria for the high-risk clinical target volume, bladder, rectum, and sigmoid. DVH estimations were obtained by subdividing training set organs-at-risk into high-risk clinical target volume boundary distance subvolumes and computing cohort-averaged differential DVHs. Full DVH estimation was then performed on the training and validation sets. Model performance was quantified by ΔD2cc = D2cc(actual)-D2cc(predicted) (mean and standard deviation). ΔD2cc between training and validation sets were compared with a Student's t test (p < 0.01 significant). Categorical variables (physician, fraction-number, total fractions, and case complexity) that might explain model variance were examined using an analysis of variance test (Bonferroni-corrected p < 0.01 threshold).
RESULTS: Training set deviations were bladder ΔD2cc = -0.04 ± 0.61 Gy, rectum ΔD2cc = 0.02 ± 0.57 Gy, and sigmoid ΔD2cc = -0.05 ± 0.52 Gy. Model predictions on validation set did not statistically differ: bladder ΔD2cc = -0.02 ± 0.46 Gy (p = 0.80), rectum ΔD2cc = -0.007 ± 0.47 Gy (p = 0.53), and sigmoid ΔD2cc = -0.07 ± 0.47 Gy (p = 0.70). The only significant categorical variable was the attending physician for bladder and rectum ΔD2cc.
CONCLUSION: A simple boundary distance-driven knowledge-based DVH estimation exhibited promising results in predicting critical brachytherapy dose metrics. Future work will examine the utility of these predictions for quality control and automated brachytherapy planning.
Copyright © 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Dose predictions; Knowledge-based planning; Machine learning; Quality control; Treatment planning

Mesh:

Year:  2020        PMID: 32513446     DOI: 10.1016/j.brachy.2020.04.008

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  5 in total

1.  ORBIT-RT: A Real-Time, Open Platform for Knowledge-Based Quality Control of Radiotherapy Treatment Planning.

Authors:  Brent M Covele; Kartikeya S Puri; Karoline Kallis; James D Murphy; Kevin L Moore
Journal:  JCO Clin Cancer Inform       Date:  2021-01

2.  Diagnosis of Cervical Cancer based on Ensemble Deep Learning Network using Colposcopy Images.

Authors:  Venkatesan Chandran; M G Sumithra; Alagar Karthick; Tony George; M Deivakani; Balan Elakkiya; Umashankar Subramaniam; S Manoharan
Journal:  Biomed Res Int       Date:  2021-05-04       Impact factor: 3.411

3.  An Improved Image Classification Method for Cervical Precancerous Lesions Based on ShuffleNet.

Authors:  Shan Fang; Jiahui Yang; Minghui Wang; Chunhui Liu; Shuang Liu
Journal:  Comput Intell Neurosci       Date:  2022-09-13

4.  A personalized DVH prediction model for HDR brachytherapy in cervical cancer treatment.

Authors:  Zhen Li; Kehui Chen; Zhenyu Yang; Qingyuan Zhu; Xiaojing Yang; Zhaobin Li; Jie Fu
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

5.  Support Vector Machine Model Predicts Dose for Organs at Risk in High-Dose Rate Brachytherapy of Cervical Cancer.

Authors:  Ping Zhou; Xiaojie Li; Hao Zhou; Xiao Fu; Bo Liu; Yu Zhang; Sheng Lin; Haowen Pang
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.